发明授权
- 专利标题： Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
-
申请号： US17749452申请日： 2022-05-20
-
公开(公告)号： US11827614B2公开(公告)日： 2023-11-28
- 发明人: Stephen M. Dalby , Clinton Scott Shultz , Chintal Desai , Joshua Lee , Zhiwei Chen , Jungchul Kim , Nastaran Salehi Marzijarani , Tao Wang , Eric M. Phillips , Patrick Larpent , Het P. Patel , Haiheng Guo , Xin Wang , Kangze Dai , Lu Chen , Teng Li , Taotao Lu , Jianjun Duan
- 申请人： Merck Sharp & Dohme LLC , Werthenstein Biopharma GMBH
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme LLC,Werthenstein Biopharma GMBH
- 当前专利权人： Merck Sharp & Dohme LLC,Werthenstein Biopharma GMBH
- 当前专利权人地址： US NJ Rahway; CH Lucerne
- 代理商 Eric A. Meade; John C. Todaro
- 主分类号： C07D317/72
- IPC分类号： C07D317/72 ; C07C317/14
摘要：
The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
公开/授权文献
信息查询
